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Abstract
Background: Callus is one of the most common foot skin complaints experienced by people of all ages. These
painful and unsightly lesions often result in disability. The ‘gold standard’ of treatment is scalpel debridement by a
trained specialist; however, people also seek over-the-counter remedies. There is a lack of clinical evidence for the
efficacy of such products, which makes selection by patients and practitioners difficult.
Methods: This randomised, three-armed, parallel, comparative trial aimed to test the efficacy of two home treatments
for plantar callus using novel, objective outcome measures (skin hydration using the capacitance method; elasticity
using negative pressure application; and surface texture using imaging). Additional outcome measures were: size of
callus, quality of life (Foot Health Status Questionnaire) and self-reported participant satisfaction and compliance. The
results were compared to a podiatry treatment. Participants were randomly allocated to one of three groups:
potassium hydroxide (KOH, 40 %); trichloroacetic acid (TCA); and podiatry treatment. Participants were followed for
3 weeks after their initial intervention appointment (days 7, 14 and 21). The primary outcomes were the change from
baseline in callus hydration, elasticity, texture, and size at each of the three time points. The secondary outcomes
where: change in quality of life 21 days after treatment; resolution of calluses via visual inspection; and participant
compliance and perception.
Results: Forty-six participants (61 ft) with plantar calluses were recruited. The podiatry treatment showed immediate
and significant changes in all objective outcomes, associated foot pain and function (p <0.01). Lesser changes in skin
quality and perceived pain and functional benefits occurred with TCA and KOH over 21 days.
Conclusions: This is the first study where objective outcome measures have been used to measure changes in the
nature of skin in response to callus treatments. We found significant differences in plantar callus in response to podiatry
and two home treatments. The podiatry treatment showed immediate and significant changes in skin and associated
foot pain and function. Lesser, but sometimes comparable, changes in skin and perceived pain and functional benefits
occurred with TCA and KOH over 21 days.
Trial registration: ISRCTN14751843: date of registration: 30 April 2015.
Keywords: Hydration, Texture, Elasticity, Potassium hydroxide, Trichloroacetic acid, Podiatry, Foot skin
* Correspondence: F.Hashmi@salford.ac.uk
1School of Health Sciences, Brian Blatchford Building, University of Salford,
Manchester M6 6PU, UK
Full list of author information is available at the end of the article
© 2016 Hashmi et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Hashmi et al. Trials  (2016) 17:251 
DOI 10.1186/s13063-016-1377-2
Background
Foot callus is a hyperkeratotic skin lesion that commonly
develops on the plantar surface of the forefoot in response
to compression, friction and shearing forces [1–3]. Being
the most common foot skin complaint in people of all
ages, many seek advice and treatment from podiatrists [4].
Calluses are considered to be a common cause of foot
pain [5, 6] and the secondary complications of these le-
sions can have a detrimental impact on the functional sta-
tus of the foot in the elderly [7–11] as well as adding to
the risk of ulceration in people with diabetes [12].
Currently, the ‘gold standard’ of treatment for calluses
is scalpel debridement [1, 2, 9] with the regular applica-
tion of topical keratolytics. Physical removal of callus
has been shown to improve quality of life (QoL) and
pain outcomes [13] although it is not clear whether this
is the case for older people [14]. Despite the initial rea-
sons for seeking treatment, the need for effective off-
the-shelf topical treatments are warranted, as regularly
clinical treatments can prove costly.
Caustic and acidic compounds such as potassium hy-
droxide (KOH) and trichloroacetic acid (TCA) are com-
mon keratolytics used in relatively low concentrations that
are known to digest epidermal keratin [15, 16]. More re-
cently these compounds have been incorporated in greater
concentrations in callus removal preparations. The little
evidence that is available as to the efficacy of these treat-
ments is based on the subjective opinions of the users ra-
ther than on objective quantitative measures of skin
properties. The measurement of the improvement of the
structure and function of foot skin and callus would
strengthen confidence in the selection of appropriate and
effective treatments. Developments in measurement tech-
nology to objectively quantify changes in skin hydration,
elasticity, texture have recently been applied successfully
to the plantar surface of the foot [17, 18]. These papers re-
port the high level of reliability of these measures for
evaluating plantar skin and their ability to identify differ-
ences between normal and hyperkeratotic plantar skin,
such as heel fissures, calluses and corns. This now pre-
sents an opportunity to objectively quantify for the first
time the effects of various treatments of plantar callus.
The aim of this study was to evaluate the effective-
ness of two common keratolytic compounds used for
the removal of plantar callus: potassium hydroxide
(KOH) and trichloroacetic acid (TCA). The measures
taken were: skin surface hydration using capacitance;
full skin elasticity using the application of negative
pressure; and skin surface texture using high-
resolution imaging. The outcomes were compared to
the ‘gold standard’ of a typical clinical podiatry treat-
ment. Hypothesis (equivalence framework): there is a
significant difference, in objective outcome measures,
between KOH/TCA therapies and podiatry treatment.
Methods
Study design
This study was a randomised, three-armed, parallel, com-
parative trial. Recruitment occurred from August 2012 to
October 2013. Participants were randomly allocated to re-
ceive one of three treatments: (1) KOH-based treatment,
(2) TCA-based treatment, and (3) clinical podiatry treat-
ment. The study protocol was reviewed and approved by
the University of Salford, Department of Health Sciences
Ethical Approval Committee (application number HSCR12/
55) and conforms to the provisions in the Declaration of
Helsinki. The protocol was registered in the ISRCTN re-
gistry (ID: ISRCTN14751843). All participants provided
written informed consent prior to taking part. The trial was
conducted at one academic clinical site (Podiatry Clinical
Facility, University of Salford, Manchester, UK).
Participant recruitment
Participants were recruited via flyers within the univer-
sity and advertisements in the local newspaper. Volun-
teers were included if they were aged 18 years and older
and had plantar callus that had not been treated in the
previous 6 weeks. This was assessed by a registered po-
diatrist. Both men and women were included.
Participants were excluded if they had any foot skin dis-
orders such as infections (e.g. athlete’s foot), dermatitis,
psoriasis, unhealed skin wounds, ulcers or blisters. Any
participant with a known systematic disease, including
peripheral vascular disease or a musculoskeletal disorder
of the foot or ankle, rheumatoid arthritis or diabetes, was
excluded. Participants were asked if they were allergic to
any topical preparations. Participants were also deemed
ineligible if they were unable to reach their feet. Volun-
teers were asked not to use any foot products (e.g. creams
and powders) during the study and for 48 h prior to the
screening appointment. If they were unable to stop using
a product due to medical or personal reasons, they were
not included in the study.
Randomisation and blinding
The random allocation sequence was generated in one
block of 90 (30 for each treatment group) with the know-
ledge that fewer participants than this would be recruited.
The allocations were concealed from the investigator enrol-
ling participants by folding the opaque paper with the allo-
cations on and placing them in sealed envelopes (as
per SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents [19] and
Consolidated Standards of Reporting Trials (CONSORT)
Statement [20], see Additional files 1 and 2). Participants
with multiple calluses were asked to nominate one callus
pre randomisation, usually the most uncomfortable or lar-
gest, which was classed as the ‘index’ callus.
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Due to the physical nature of the treatments, and their
effects on the skin, the participants and the investigator
could not be blinded to them. With regard to the out-
come measures, these were self-reported outcome mea-
sures and objective skin evaluation measures apart from
the evaluation of the photographs which have the poten-
tial to be subject to assessor bias. Therefore, we miti-
gated for this by ensuring that the images were coded
before quantitative evaluation of the size of the calluses
was carried out and, more importantly, there was a suffi-
cient time period between the coding, analysis and
uncoding processes. This was typically 14 days, and lim-
ited the ability of the assessor to associate a photograph
with a specific patient and treatment group. In addition,
the photographs were of the forefoot only and, therefore,
did not have any features that allowed the participant to
be identified.
Interventions
The KOH (40 %, Balsan® Callus Removal Lotion) and
TCA (concentration unknown, Wartner® Corn and
Callus Removal Pen) treatments are available as over-
the-counter remedies. Participants were advised to fol-
low the manufacturer’s instructions. The KOH product
was applied by the participants at weekly intervals in the
research clinic. The corrosive action of KOH on rela-
tively healthy skin is a known risk factor. According to
the manufacturer’s instructions regarding the application
of the product, there was a risk that the KOH could
come in contact with healthy skin, therefore increasing
the risk of corrosive damage. To comply with ethical re-
quirements, application by the participant in a clinical
environment was deemed more appropriate. The treat-
ment involved soaking a cotton wool pad with the liquid
and placing it in contact with the callused skin for
15 min, followed by manually scraping the softened tis-
sue with a blunt spatula. The participants were given an
instruction leaflet provided by the product manufacturer
after randomisation into the treatment group. In the
case of the TCA treatment, participants applied the li-
quid to the callused skin after soaking the foot in water
for 10 min and then lightly rubbing the surface of the
callus with an emery board. The participants were ad-
vised to do this for four consecutive days followed by
4 days of not using the treatment and then 4 days using
the treatment, etc.
The participants in the podiatry group received a typ-
ical clinical podiatry treatment on the first day of the
study (day D0), after which no treatment was given at
follow-up appointments. The treatment involved sharp
debridement (using a scalpel) followed by the use of a
fine sandpaper sanding disc (Moore’s disc) on an elec-
trically powered rotating device (20,000 rpm). The use of
the sanding disc was necessary to provide a seamless
transition and, therefore, a clear view of the area of skin
at the edge of the callus, i.e. between the removed callus
area and the adjacent normal skin. This was necessary in
some (not all) cases depending upon the geometry of the
callus surface post debridement, which varies naturally
due to skin type. This clearer view ensured correct
placement of measurement probes on the uncallused
skin site. Nonetheless, the amount of callus removed
using this method was very small (less than 1 mm). Also,
the measures were taken from the centre of the callus
and, therefore, the impact of filing with the disc would
be minimal on the outcome measures.
Outcome measures
The primary outcome decided a priori was the change in
hydration, elasticity, skin surface texture and callus size
at all time points (D7, D14 and D21) compared to D0
for the KOH and TCA groups and compared to D0 post
treatment for the podiatry group. The secondary out-
come measures were: (1) change in QoL before and
21 days after treatment, (2) change in biophysical out-
come measures on D7, D14 and D21 in the podiatry
treatment group.
Subjective outcome measures
The number of calluses resolved at D21 for the KOH
and the TCA groups and D0 immediately after treatment
for the podiatry group were noted. Resolution was de-
fined as the absence of index callus on visual inspection
of the skin.
A validated QoL questionnaire (the Foot Health Status
Questionnaire, FHSQ) was completed by each partici-
pant [21] on D0 and D21 of the trial. The FHSQ has
been widely used in foot pain research and provides a
score for overall foot health-related QoL. This paper re-
ports the separate scores for foot pain, foot function, and
general foot health domains. For appropriate interpret-
ation of the results the minimal important difference
(MID) was considered, where the MID for pain was 13
points and 7 points for foot function. The MID for the
general foot health domain was 0 points [22].
Biophysical outcome measures and protocols
Prior to performing measurements, participants’ foot
skin was allowed to acclimatise to room temperature
and humidity conditions for at least 15 min. The partici-
pant sat on a plinth with legs extended and the plantar
aspects of both feet facing the investigator.
Marking of the callus and control skin sites Using a
ruler the callus plaque was bisected along the horizontal
and vertical axes and the centre was marked. An un-
affected skin site in the region of the plantar aspect of
the fifth metatarsal base was selected to be the control
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site. A detailed description of the reliability of the mark-
ing of the skin is described in Hashmi et al. [18].
Digital image capture Photographs of the calluses were
taken at all data collection appointments using a digital
camera (Canon PowerShot SX210 IS, 14.1 mega pixels).
A standard protocol was used for every photograph cap-
tured. A white card was placed behind the foot before
capturing the image. Each foot was positioned so that
the callus was central to the camera’s field of view. The
camera was placed at a distance of approximately 10 cm
away from the callus. All attempts were made to ensure
that the front of the camera was perpendicular to the
foot. The same lighting was used for every data collec-
tion session. The photographs were used for the subject-
ive assessment of change in callus size and also for
measuring callus size.
Skin measurement devices The devices used were the:
Corneometer® CM 825, Cutometer® 580 MPA and
Visioscan® VC 98 (Courage-Khazaka, Cologne, Germany).
These measured hydration, elasticity and skin surface tex-
ture respectively. Intra and intertester reliability and the
standard error of measurement (SEM) for these devices
on foot skin have been confirmed in previous work [18].
Callus area calculations The approximate area of each
callus was calculated using the following equations: πr2 for
circular plaques and πab for oval plaques (where r = radius,
a = first radius of oval and b = second radius of oval).
Participant perception and compliance
Participant perception Participants were asked, on D21
for the KOH and TCA groups and immediately after po-
diatry treatment of D0, whether they thought that their
callus had improved in appearance according to the fol-
lowing Likert scale: a great deal, much, somewhat, a lit-
tle, and not at all.
Intervention use Treatment compliance was monitored
via questionnaires provided at each measurement ap-
pointment regarding the number of times the treatment
was not used over the 7 days preceding the measure-
ment interval.
Collection and management of data
Baseline data were collected at the clinical appointment
prior to randomisation. All the outcome measures sub-
sequent to baseline were completed on the return ap-
pointments on D7, D14 and D21. At regular intervals
during the study, a representative of the sponsor’s team
visited the study centre. At each monitoring visit, the
chief investigator and the monitor reviewed the study
progress, compliance to the study protocol, and any emer-
gent problems (e.g. adverse events or recruitment issues).
The academic research team (Trial Management Group)
held regular meetings, independent from the sponsor,
throughout the study period to monitor: unblinded base-
line data, safety of the participants, and any ethical issues.
All data were treated with the strictest confidence and
in accordance with the Data Protection Act 1998. Paper
documents were retained in a secure cabinet in a locked
room both during and after trial completion. During the
course of the trial any personal identifiable paper
records were stored separately from anonymised paper
records. Once the study was complete, data were ar-
chived on the University of Salford campus, with access
restricted to the research team only. All electronic re-
cords will be stored indefinitely on a secure, password-
protected server within the University of Salford.
Sample size and statistical analysis
A sample size of 60 (i.e. 20 callus lesions per group) pro-
vided an 80 % probability of detecting a difference be-
tween interventions of 5 arbitrary units (AU) (standard
deviation 3 AU) of skin surface hydration readings using
the Corneometer® by D21 (ɑ = 0.05). These estimates
were taken from one published study that focussed on
measuring the efficacy of cream treatment for dry heel
skin over a period of 14 days [13]. There are no pub-
lished studies that have tested the effects of callus treat-
ments using the outcome measures used in our study.
The results were analysed and reported in two ways:
(1) all data were analysed by intention-to-treat analysis.
For all missing data a multiple imputation method using
Amellia II software was used to generate missing at ran-
dom data [23]. Continuous data were tested initially
for deviation from the assumption of a normal distri-
bution using the Shapiro-Wilk test of normality. The
majority of the variables were not normally distrib-
uted; therefore, non-parametric inferential statistical
tests were used; and (2) the number of resolved calluses
according to visual inspection of the photographs was
expressed as an odds ratio (OR). Statistical significance
was set at p ≤0.01.
In the situation where individual questions within the
FHSQ remained unanswered, the middle value on the
response scale was assumed. This was done provided no
more than 50 % of the responses for that particular sub-
domain were missing. Where more than 50 % of the re-
sponses in a subdomain were missing the total score for
that subdomain was not calculated.
Progression of participant through the trial
Forty-six people were recruited to the study, of which 15
had callus on both feet. Thirty-one people had callus on
one foot only. Therefore, a total of 61 callus lesions and
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feet were evaluated. The progression of the participants
through the trial is presented in Fig. 1. There was a
relatively small amount of missing data that required
imputation. Ten participants were lost to follow-up
by D21. Non-attendance figures for D7 and D14 are
stated in Fig. 1.
Adverse event reporting
Adverse events (including assessment of the seriousness,
causality, expectedness, and intensity of the event/re-
action) were recorded on an adverse event form, as ap-
propriate. Participants were asked at each trial visit
whether they had had any problems following their treat-
ment and if any adverse events had occurred. The adverse
event reaction reporting period for this trial began when
the participant was randomised into the study and ended
21 days after the date of randomisation.
Potential complications associated with the treat-
ments were pain or skin irritation. The criteria for
discontinuing the allocated interventions for a given
trial participant were: participant request, worsening
of symptoms (such as pain), or irritant reactions to
the topical therapies.
Results
There were no adverse events. The majority of the rea-
sons for non-attendance on D7 and D14 were related to
participant personal matters and were not related to the
interventions. The reasons for the 10 people not attend-
ing the D21 appointments are not known.
Baseline data
The average room temperature and relative humidity were
23.6 ± 1.0 °C and 53.1 ± 8.4 % respectively. Table 1 provides
the baseline characteristics of participants including the
FHSQ data before randomisation. Sixty-one feet were ran-
domised into the three treatment groups. Age ranged
from 23 to 78 years (median 48, interquartile range
(IQR) 24 years) and all groups were primarily female
(84 %, 51/61). The three groups were balanced with
respect to demographic data and there was no signifi-
cant difference between the groups. With regards to
baseline FHSQ data there were also no statistically
significant differences between the groups for all the
subdomains. However, when considering MID be-
tween the groups the pain domain (MID = 13 points)
for the podiatry group score was significantly lower
than the KOH and TCA groups. The foot function
Fig. 1 Progression of the participants through the trial. Primary end point at D21. Study design using CONSORT Statement guidelines [20].
*n represents the number of people, ∞n represents the number of feet, DNA did not attend
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(MID = 7 points) and general foot health (MID = 0
points) domain scores all differed significantly be-
tween groups at baseline. Baseline data for the phys-
ical properties of the skin are reported in Table 2.
The data in the groups are not as well-balanced as
those of the demographic data and, therefore, the
subsequent results are described as differences from
baseline as opposed to absolute values.
Primary outcomes
Intention-to-treat analyses All four outcome measures
showed statistically significant improvement compared
to baseline measures immediately after podiatry treat-
ment (p = 0.00). The calluses from both the KOH and
TCA groups demonstrated an increase in hydration with
time, apart from D14 where a reduction in hydration
was noted in the KOH group. Increase in hydration
compared to baseline was statistically significant on D7
and D21 in the KOH group and on D14 and D21 in the
TCA group. Pairwise comparisons between the groups
showed significant differences between the topical prep-
arations and podiatry treatment. Improvement in skin
elasticity (p = 0.04 and p = 0.91) and skin surface texture
(p = 0.33 and p = 0.04) at D21 compared to baseline, was
not significantly different for either group (Fig. 2). The
callus plaques were significantly smaller in the KOH and
TCA groups (p = 0.00). Pairwise comparisons (Table 3)
showed no significant difference between the KOH and
TCA groups in all outcome measures by D21. The
podiatry treatment outcomes at D0 showed significant
improvement in all outcomes compared to the KOH
and TCA groups. There were no significant differences
(p >0.01) in any measures at any time point at the
control site (fifth metatarsal).
The KOH and TCA treatments demonstrated a grad-
ual improvement in hydration and texture with time,
apart from D14 where a reduction in hydration was
noted in the KOH group and deterioration in texture in
the TCA group. The elasticity of the skin improved
gradually with time in the KOH group; however, the skin
treated with TCA became less elastic with time. There
was no significant difference between the groups at each
time point with regards to hydration and elasticity mea-
sures; however, at D7 the skin texture had improved sig-
nificantly in the TCA group compared to the KOH
group (p = 0.00). The measurements taken from plantar
skin after podiatry treatment showed a gradual increase
in hydration and texture and a significant decrease in
elasticity with time.
Figure 3 shows a significant reduction in callus surface
area for D7, D14 and D21 for both treatment groups ex-
cept for D7 in the TCA group. In this case the area of
the callus increased (median increase in surface area:
0.20 mm2, IQR: 0.99 mm2). At D21 both groups showed
a similar reduction in callus size: KOH and TCA median
change in surface area: 0.81 cm2, 0.80 cm2 respectively.
Subjective outcome measures
Callus resolution
Odds ratios At 21 days post treatment 20 % (4/20) of
the calluses had resolved in the KOH group compared
to 0 % (0/20) in the TCA group (OR: 11.2, 95 % CI: 0.56
to 222.99, p = 0.11 in favour of the KOH group). The
odds of a completely resolved callus were over 11 times
greater for KOH treatment compared to the TCA at
Table 1 Baseline characteristics of all participants
Variable Type of intervention
Podiatry (n = 21) KOH (n = 20) TCA (n = 20)
Age (years)
Median 52 54 43.5
Min, max 24, 68 23, 73 24, 68
IQR 24.5 26.75 19
Sex (% female) 86 85 80
Height (m)
Median 1.57 1.65 1.47
Min, max 1.42, 1.98 1.47, 1.88 1.49, 1.88
IQR 0.23 0.11 0.18
Weight (kg)
Median 78.25 68.50 84.5
Min, max 46.3, 111.6 46.3, 101.6 57.0, 95.3
IQR 36.07 21 18.25
BMI (kg/m2)
Median 27.5 26 29
Min, max 19, 41 20, 36 22, 41
IQR 9.75 4.75 6.25
FHSQ score: range from 0–100
Foot pain
Median 54.06 80.00 81.25
Min, max 12.5, 100 35.63, 100 25, 100
IQR 60.47 31.72 50.31
Foot function
Median 84.38 100 93.75
Min, max 25, 100 68.75, 100 43.75, 100
IQR 48.44 31.72 25.00
General foot health
Median 33.75 51.25 60
Min, max 0, 60 25, 100 0, 100
IQR 56.88 39.38 56.88
BMI body mass index, FHSQ Foot Health Status Questionnaire, IQR interquartile
range, KOH potassium hydroxide, TCA trichloroacetic acid
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21 days. However, these data did not reach significance.
All calluses were resolved immediately after podiatry
treatment on D0.
Quality of life measures
There were no statistically significant differences in QoL
measures (foot pain, foot function and general foot
health domains) at D21 post KOH and TCA treatments
compared to baseline, nor immediately after podiatry
treatment on D0 (Table 4). However, when considering
the MID of the subdomains, all the treatment groups
showed an improvement in pain of above 13 points
(MID = 13); and an improvement of above 8 points
(MID = 0) for general foot health. The change in foot
function score was below the MID of 7 for all three
groups.
Patient perception data
All participants (100 %, 21/21) who received the podiatry
treatment perceived the treatment to have improved the
condition of their skin ‘a great deal’ on D0. Eighty-two
per cent (17/21) of the same group declared an improve-
ment of either ‘much’ or ‘a great deal’ by D21. This com-
pares to 65 % (13/20) in both KOH and TCA groups.
Experience of use data
Only two people reported not using the TCA treatment
according to the instructions on the pack between D14
and D21. One participant used the product twice rather
than on four occasions, the other used it once.
Discussion
This study aimed to measure and compare the structural
and functional changes of plantar callused skin with use
of two home treatments and in response to a clinical po-
diatry treatment. This is the first time that the efficacy of
a range of callus treatments has been assessed using spe-
cific biophysical outcome measures taken at regular in-
tervals over 21 days.
While all the outcome measures improved by D21
compared to baseline for all three treatment groups,
only the podiatry group showed a statistically significant
improvement in all skin biophysical measures, and only
for immediately post treatment (p ≤0.01). Increased
hydration and reduced callus surface area were statisti-
cally significantly different for all three treatment groups
by D21 compared to baseline. However, despite the hy-
dration increasing, elasticity did not change significantly
for KOH and TCA groups. This would suggest that
three things might be taking place: (1) the SC cells
themselves have not shed from the bulk of the callus but
have absorbed a degree of moisture as a result of the
chemical actions of the compounds, and/or (2) a small
amount of the very superficial layers of the SC have suc-
cessfully desquamated from the bulk of the tissue but
not enough to cause a significant change in the elasticity
Table 2 Baseline data for the podiatry, potassium hydroxide (KOH) and trichloroacetic acid (TCA) groups
Skin sites
Podiatry (n = 21) KOH (n = 20) TCA (n = 20)
Callus Control Callus Control Callus Control
Skin property
Skin surface hydration (AU)
Median 2.83 8.67 1.96 9.05 3.45 10.35
Min, max 0.00, 15.55 3.03, 22.0 0.20, 16.07 3.5, 50.41 0.48,13.24 0.36,28.37
IQR 3.46 7.98 1.96 8.10 3.07 10.02
Elastic properties of the skin (mm)
Median 0.33 0.87 0.52 0.89 0.47 1.02
Min, max 0.00, 1.29 0.48, 1.42 0.00, 1.13 0.64, 1.40 0.04, 1.27 0.69, 1.39
IQR 0.59 0.26 0.58 0.23 0.56 0.22
Skin surface texture or scaliness (AU)
Median 1.02 0.84 0.91 0.88 1.19 0.84
Min, max 0.52, 1.65 0.40, 2.89 0.52, 2.84 0.38, 2.81 0.65, 2.19 0.38, 2.46
IQR 0.50 1.49 0.57 0.88 0.52 1.00
Surface area [cm2]
Median 3.42 2.02 2.16
Min, max 0.44, 9.42 0.28, 9.54 0.39, 5.50
IQR 3.19 2.55 2.92
AU arbitrary units, IQR interquartile range
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of the SC (the surface area data support this), or (3) ex-
posure of some underlying callus tissue that is naturally
more hydrated. The only way to appropriately test this hy-
pothesis is to measure SC thickness as the treatments take
effect. This is difficult to achieve using ultrasound as the
densely packed SC of plantar skin acts as a barrier to the
sound waves [24]. However, optical coherence tomography
(OCT) produces high-resolution images of the stratum
corneum akin to those of histology sections and could be a
viable option for future research of this kind [25].
In general the biophysical parameters for the KOH
and TCA treatments showed similar improvement with
time, except for skin surface texture. The KOH-treated
callus showed consistent improvements throughout the
trial whereas TCA-treated skin showed deterioration on
D7 followed by improvements on D14 and D21. These
data matched the progressive change in the visual ap-
pearance of the skin. After the first week of TCA the
callus had loosely adhered sheets of SC (Fig. 4). This
scaling skin may act as a barrier for TCA access to the
underlying tissue and a more aggressive form of physical
debridement is perhaps required.
The podiatry treatment group data have been inter-
preted in two ways. Firstly, by comparing the immediate
improvement in the biophysical outcome measures to
those at specific time points of the KOH and TCA
groups. This was used to test how long it would take for
the topical treatments to have an effect similar to that of
podiatry treatment. With the exception of hydration in
the TCA group on D14 and D21 the KOH and TCA
data did not match that of the post-podiatry treatment
measures. Secondly, comparing the quantitative mea-
sures of the skin after 21 days of topical treatment and
21 days after podiatry treatment showed no significant
differences between the groups, and all groups reported
clinically significant improvements in foot pain and gen-
eral foot health. This suggests that in the absence of ac-
cess to clinical treatment the use of home treatments
may be of benefit to some sufferers.
The majority of the participants in all three groups re-
ported that the appearance of the callus improved either
by ‘much’ or ‘a great deal’ by the end of the trial period.
Improvement in foot pain and general foot health per-
ception had also improved in all the groups by greater
than the recommended MID value, although the podia-
try group scores were higher than those of the KOH and
TCA group scores. The improvement in perception data
thus matches that of the quantitative outcomes, implying
Fig. 2 Median change in hydration, elasticity, and texture for plantar callus at D7, D14 and D21 for potassium hydroxide (KOH), trichloroacetic acid
(TCA) and podiatry treatment groups. Change in a negative direction of hydration and elasticity data represents a decrease in hydration and elasticity
respectively. Change in a negative direction of texture data represents an improvement in texture. *represents a significant difference (p ≤0.01)
compared to baseline (the podiatry group baseline values were those taken post podiatry treatment on D0)
Hashmi et al. Trials  (2016) 17:251 Page 8 of 11
that as the biophysical properties of the skin improve so
do the perceptions of associated pain and general foot
health.
All groups reported a reduction in pain greater than
the MID of 13 points but since participants were not
blinded to the treatments some placebo effect is pos-
sible. It is known that placebo effects due to expectation
and conditioning are often acute responses (up to
2 weeks in pain studies) [5]. The 3-week trial time for
our study may exceed these limits, but we cannot be
sure. Landorf et al. [14] have previously shown no sig-
nificant difference in terms of foot pain between podia-
try and sham callus treatment groups.
The improvement in skin quality suggests that that the
use of home treatments would be an appropriate adjunct
to podiatry treatments in managing plantar callus: for
example, between clinical appointments, and could per-
haps help suffers lengthen the time between clinical
appointments.
Prior clinical trials used observation and perception
data to test the efficacy of callus treatments, relying on
categorical data (i.e. the presence or absence of callus
and evaluating changes in pain levels). The OR analysis
of our data showed that the two home treatments were
relatively ineffective whereas the objective measures in-
dicate structural changes in specific qualities of the skin
and that these were perceived by suffers.
The results of this study need to be viewed in light of
a number of potential limitations. Firstly, this study was
based at a single centre which poses the question of ex-
ternal validity. We are confident of the scientific rigour
of the study but invite clinicians to compare the context
Fig. 3 Change in surface area of the calluses in the potassium hydroxide (KOH) and trichloroacetic acid (TCA) treatment groups at D7, D14 and
D21. Note that the greater the change in a positive direction the smaller the callus plaque and vice versa. *represents a significant difference
compared to baseline (p = 0.00)
Table 3 Pairwise comparisons between the three groups for change in hydration, elasticity, skin surface texture and callus area by
D21
Median difference (p value)
Hydration (AU) Elasticity (mm) Skin surface texture (AU) Callus area (cm2)
Podiatry vs KOH 4.31: 0.91 (0.00) 0.33: 0.08 (0.00) 0.00: −0.04 (0.00) 3.24: 0.81 (0.00)
Podiatry vs TCA 4.31: 1.60 (0.03) 0.33: −0.01 (0.00) 0.00: −0.25 (0.00) 3.24: 0.43 (0.00)
KOH vs TCA 0.91: 1.60 (0.28) 0.08: −0.01 (0.53) −0.04: −0.25 (0.43) 0.81: 0.43 (0.97)
AU arbitrary units, KOH potassium hydroxide, TCA trichloroacetic acid
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of the trial with their own clinical situation. Secondly,
due to the nature of the effects of the treatments on the
skin participant blinding was not possible. This could
have introduced bias with regard to patient-reported
outcomes. We did, however, mitigate for assessor bias by
ensuring appropriate blinding measures for the evalu-
ation of callus size from the photographic data. Thirdly,
the long-term benefits and the cost-effectiveness of the
treatments have not been analysed in this study.
Although this was initially considered, it was decided
that the focus of the study should be primarily on testing
for the immediate effects. The results would then inform
a longer-term clinical and cost-effectiveness study which
would consider callus recurrence rates. For example,
podiatry treatment may provide exceptional short-term
success but callus recurrence rate may imply that long-
term success would likely be no better than the topical
treatments. At this stage it may be assumed that podia-
try treatment is more expensive compared to over-the-
counter home treatments (given health care costs and
models of care) but longer-term outcome may modify
this view in terms of cost-effectiveness. Finally, as with
all studies of this nature, the issue of monitoring patient
compliance must be considered. The 21-day timescale
was considered to be both practical given the burden on
the users, appropriate with regard to consumer expecta-
tions of home treatments, and encouraging of compli-
ance in terms of motivation and continued engagement.
The TCA treatment was the only treatment used at
home by the participants and TCA dispensers were not
weighed at the end of the study, although this would
only measure dispensed TCA amount rather than dose
used. Compliance was evaluated via self-reported use
data from the participants, which was further confirmed
by the distinctive, flaky appearance of the callus during
the review appointments. Figure 4 in the paper depicts
the typical appearance of the callus during the TCA
treatment period and, based on this, there were no
grounds for suspicion of non-compliance.
Conclusions
Using objective measures of skin structure and function,
we found significant differences in plantar callus in re-
sponse to podiatry and two home treatments. The po-
diatry treatment showed immediate and significant
changes in skin and associated foot pain and function.
Lesser but sometimes comparable changes in skin and
perceived pain and functional benefits occurred with
TCA and KOH over 21 days.
Fig. 4 Photograph of a region of plantar callus after 7 days of TCA-
based treatment use
Table 4 Change from baseline in the total scores from the Foot
Health Status Questionnaire (FHSQ) at D21 (for KOH and TCA
treatment groups and podiatry treatment on D0). A higher
score is favourable
Variable Podiatry
(n = 21)
NaOH
(n = 20)
TCA
(n = 20)
Foot pain
Change from baseline
Median 18.13 13.44 13.34
Min, max −26.88, 64.38 −6.25, 33.75 −2.11, 68.75
IQR 48.75 15.93 33.28
Pairwise comparisons P
Podiatry vs NaOH 0.80
Podiatry vs TCA 0.83
KOH vs TCA 0.45
Foot function
Change from baseline
Median 6.25 0.00 5.73
Min, max −12.50, 62.50 0.00, 31.25 −6.27, 56.25
IQR 21.88 12.50 23.44
Pairwise comparisons P
Podiatry vs NaOH 0.36
Podiatry vs TCA 0.79
KOH vs TCA 0.48
General foot health
Change from baseline
Median 25.00 8.75 13.46
Min, max −17.50, 92.50 −40.00, 100 −20.01, 72.50
IQR 63.13 45.63 41.30
Pairwise comparisons P
Podiatry vs NaOH 0.11
Podiatry vs TCA 0.24
KOH vs TCA 0.66
IQR interquartile range, KOH potassium hydroxide, NaOH sodium hydroxide,
TCA trichloroacetic acid
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